Bengaluru: For years, oral cancer in India has been viewed through the lens of male tobacco use, even though women in parts ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW ...

Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...

Alcohol and tobacco use are two of the most important risk factors for head and neck cancers. However, a large portion of new head and neck diagnoses are being driven by cancer-causing types of human ...

Phase I clinical trials remain essential for new drug development, identifying new treatment pathways, and identifying optimal dosing, the American Society of Clinical Oncology emphasized in a new ...

L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

Primary pulmonary nuclear protein of the testis (NUT) midline carcinoma (NMC) is an extremely rare, highly aggressive thoracic malignancy that ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...